Fresenius Medical Care Reports Q3 2024 Results
Ticker: FMCQF · Form: 6-K · Filed: Nov 5, 2024 · CIK: 1333141
| Field | Detail |
|---|---|
| Company | Fresenius Medical Care Ag (FMCQF) |
| Form Type | 6-K |
| Filed Date | Nov 5, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: earnings, financial-results, press-release
Related Tickers: FME
TL;DR
FME dropped Q3 results Nov 5th, includes non-GAAP numbers.
AI Summary
Fresenius Medical Care AG announced its third quarter results for the period ending September 30, 2024, on November 5, 2024. The company issued a press release detailing these results, which include non-GAAP financial measures.
Why It Matters
This filing provides investors with the latest financial performance data for Fresenius Medical Care, crucial for understanding the company's current operational health and future prospects.
Risk Assessment
Risk Level: low — This is a routine earnings release and does not contain significant new risks or material adverse events.
Key Players & Entities
- Fresenius Medical Care AG (company) — Registrant
- November 5, 2024 (date) — Date of Press Release
- September 30, 2024 (date) — End of Reporting Period
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report Fresenius Medical Care AG's third quarter results for the period ending September 30, 2024, via a press release.
When did Fresenius Medical Care AG issue the press release for its third quarter results?
The press release was issued on November 5, 2024.
What period do the reported third quarter results cover?
The results cover the period ending September 30, 2024.
Are the financial figures in the press release exclusively GAAP measures?
No, the attached Press Release contains non-GAAP financial measures.
What exhibits are associated with this filing regarding the Q3 results?
Exhibit 99.1 contains the Press Release, and Exhibit 99.2 contains the corresponding financial figures.
Filing Stats: 569 words · 2 min read · ~2 pages · Grade level 15.8 · Accepted 2024-11-05 06:01:40
Filing Documents
- tm2425314d2_6k.htm (6-K) — 16KB
- tm2425314d2_ex99-1.htm (EX-99.1) — 70KB
- tm2425314d2_ex99-2.htm (EX-99.2) — 667KB
- tm2425314d2_ex99-1img001.jpg (GRAPHIC) — 5KB
- tm2425314d2_ex99-1img002.jpg (GRAPHIC) — 89KB
- tm2425314d2_ex99-1img003.jpg (GRAPHIC) — 89KB
- tm2425314d2_ex99-1img004.jpg (GRAPHIC) — 119KB
- tm2425314d2_ex99-2imgb001.jpg (GRAPHIC) — 3KB
- 0001104659-24-114039.txt ( ) — 1173KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. DATE: November 5, 2024 Fresenius Medical Care AG By: /s/ Helen Giza Name: Helen Giza Title: Chief Executive Officer and Chair of the Management Board By: /s/ Martin Fischer Name: Martin Fischer Title: Chief Financial Officer and member of the Management Board